Macrophage-mediated myelin recycling fuels brain cancer malignancy.

cancer immunity cholesterol glioblastoma lipid metabolism macrophages myelin recycling tumor microenvironment

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
07 Aug 2024
Historique:
received: 27 05 2023
revised: 26 04 2024
accepted: 18 07 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 13 8 2024
Statut: aheadofprint

Résumé

Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their cholesterol accumulation, are epigenetically rewired, display immunosuppressive features, and are enriched in the aggressive mesenchymal glioblastoma subtype. Engulfment of cholesterol-rich myelin debris endows subsets of TAMs to acquire an LLM phenotype. Subsequently, LLMs directly transfer myelin-derived lipids to cancer cells in an LXR/Abca1-dependent manner, thereby fueling the heightened metabolic demands of mesenchymal glioblastoma. Our work provides an in-depth understanding of the immune-metabolic interplay during glioblastoma progression, thereby laying a framework to unveil targetable metabolic vulnerabilities in glioblastoma.

Identifiants

pubmed: 39137777
pii: S0092-8674(24)00824-9
doi: 10.1016/j.cell.2024.07.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests L.A., D.J.K., A.K., and J.E. are inventors on European patents P091147NL and P099572EP describing relevant claims and their therapeutic potential.

Auteurs

Daan J Kloosterman (DJ)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Johanna Erbani (J)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Menno Boon (M)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Martina Farber (M)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Shanna M Handgraaf (SM)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Masami Ando-Kuri (M)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Elena Sánchez-López (E)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Bauke Fontein (B)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Marjolijn Mertz (M)

Bioimaging Facility, Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Marja Nieuwland (M)

Genomics Core Facility, Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Ning Qing Liu (NQ)

Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.

Gabriel Forn-Cuni (G)

Institute of Biology Leiden, Leiden University, Leiden, the Netherlands.

Nicole N van der Wel (NN)

Electron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.

Anita E Grootemaat (AE)

Electron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.

Luuk Reinalda (L)

The Institute of Chemical Immunology, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.

Sander I van Kasteren (SI)

The Institute of Chemical Immunology, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.

Elzo de Wit (E)

Division of Gene Regulation, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Brian Ruffell (B)

Department of Immunology, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Ewa Snaar-Jagalska (E)

Institute of Biology Leiden, Leiden University, Leiden, the Netherlands.

Kevin Petrecca (K)

Montreal Neurological Institute-Hospital, McGill University Health Centre and Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada.

Dieta Brandsma (D)

Department of Neuro-Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066CX Amsterdam, the Netherlands.

Alexander Kros (A)

Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.

Martin Giera (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Leila Akkari (L)

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands. Electronic address: l.akkari@nki.nl.

Classifications MeSH